Glucagon-like peptide 1 receptor (GLP-1R)

The Glucagon-like peptide 1 receptor (GLP-1R) is a G protein-coupled receptor that binds glucagon-like peptide 1, an incretin hormone central to metabolic regulation. GLP-1R activation stimulates glucose-dependent insulin release, inhibits glucagon secretion, delays gastric emptying, and promotes satiety. While primarily targeted for type 2 diabetes and obesity, GLP-1R also modulates gallbladder function. Agonism of GLP-1R can delay gallbladder emptying, which is associated with an increased risk of gallstone formation and cholecystitis, representing a notable safety concern for GLP-1R agonist therapies.

Other names

GLP1RGlucagon-like peptide-1 receptor

Agonism at the Glucagon-like peptide 1 receptor (GLP-1R) activates downstream signaling pathways (e.g., cAMP), leading to glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and increased satiety. In the context of gallbladder function, GLP-1R agonism contributes to delayed gallbladder emptying, affecting bile flow and potentially leading to gallstone formation.